Replies to post #11968 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>How will this reduce GTCB's cash burn rate going forward? How much of current "ongoing" expenditures might be affected by this deal?<

There is no offloading of existing cash burn because GTC’s clinical trial of ATryn in HD is already done. GTC will continue with the BLA submission for the HD indication on its own dime.